- Around 17% of children and teenagers starting GLP-1 medicines were diagnosed with a nutritional deficiency or related complication within 12 months.
- Vitamin D deficiency was the most commonly recorded problem, affecting 12.4% of the group.
- The study used health insurance records and cannot prove the medicines themselves caused the deficiencies.
GLP-1 medicines are increasingly being used to treat type 2 diabetes, severe obesity and related metabolic conditions.
As their use expands into younger age groups, researchers are asking an important question: are children receiving enough nutritional support alongside the medication?
A new US study suggests there may be room for improvement.
Researchers analysed insurance records from 2,031 young people aged 10 to 17 who started a GLP-1 receptor agonist between 2017 and 2022.
None had a recorded nutritional deficiency before starting treatment.
Within six months, 10.2% had been diagnosed with at least one nutritional deficiency or related complication.
By one year, that had risen to 16.8%, or around one in six.
The most common problem was vitamin D deficiency, diagnosed in 12.4%.
Nutritional anaemia affected around 1.6%, iron-deficiency anaemia around 1.4% and recorded muscle loss around 0.8%.
This matters because children and teenagers are still growing.
A treatment that reduces appetite can be useful for weight management, but calorie reduction should not come at the expense of protein, vitamins, minerals or normal development.
The study also found surprisingly limited access to nutrition support.
Only 5.8% had a nutrition consultation within 30 days of starting treatment.
By six months, the figure was still only 23.3%, with the average first consultation occurring around five months after treatment began.
That does not necessarily mean nutritional care prevents deficiencies.
In fact, deficiencies were diagnosed more often in young people who saw a nutrition professional, which may simply mean they were referred because a problem had already been identified or were tested more thoroughly.
There are other limitations.
Most participants were taking liraglutide, while only around 9% were taking semaglutide.
The data also came from 2017 to 2022, before newer GLP-1 treatment became as widely used as it is today.
- New GLP-1 review shows weight loss drugs are getting stronger
- GLP-1 medicines not linked to major mental health harm in new review
And because this was a claims study, it records diagnoses rather than detailed food intake or blood results.
So it cannot prove that GLP-1 medicines directly caused these nutritional problems.
But it raises a sensible clinical point.
When medication significantly changes appetite and weight loss, nutritional quality becomes more important, not less.
Young people using these medicines need treatment that includes food quality, adequate protein, micronutrients and healthy growth rather than focusing only on the number on the scales.
That fits with the wider principle that diabetes treatment works best when medication is combined with appropriate dietary and lifestyle support.
Anyone taking these medicines should also understand their known side effects and warning signs.
For younger people in particular, prescribing a GLP-1 medicine should be the beginning of structured support rather than the end of the conversation about nutrition.
Study link: https://doi.org/10.1177/21532176261486979
